Insight Molecular Diagnostics Inc. Market Cap ($96.86 Million)
Market Cap & Net Worth: Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. market cap. Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) has a market capitalization of $96.86 Million ($96.86 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19127 globally and #4419 in its home market, demonstrating a 4.23% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Insight Molecular Diagnostics Inc.'s stock price $2.96 by its total outstanding shares 32724284 (32.72 Million). Also see IMDX cash flow conversion for how efficiently the company converts equity into cash flow.
Insight Molecular Diagnostics Inc. Market Cap History (2025–2026)
Insight Molecular Diagnostics Inc. market cap history from 2025 to 2026. Data shows growth from $245.43 Million to $96.86 Million (0.00% CAGR). Check IMDX stock price for real-time trading data and today's change.
Insight Molecular Diagnostics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Insight Molecular Diagnostics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Insight Molecular Diagnostics Inc. (IMDX) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
60.53x
Insight Molecular Diagnostics Inc.'s market cap is 60.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $245.43 Million | $4.05 Million | -$50.22 Million | 60.53x | N/A |
Competitor Companies of IMDX by Market Capitalization
Companies near Insight Molecular Diagnostics Inc. in the global market cap rankings as of November 1, 2026. Also see IMDX total assets for a full breakdown of the balance sheet.
Key companies related to Insight Molecular Diagnostics Inc. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $164.04 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #480 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #530 globally with a market cap of $51.40 Billion USD ( CN¥351.23 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $697.00 |
| #143 | Danaher Corporation | NYSE:DHR | $164.04 Billion | $232.23 |
| #480 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $414.30 |
| #530 | WuXi AppTec Co Ltd | SHG:603259 | $51.40 Billion | CN¥142.01 |
Market Capitalization of Insight Molecular Diagnostics Inc. (2025–2026)
Market capitalization of Insight Molecular Diagnostics Inc. from 2025 to today. Between 2025 and today, Insight Molecular Diagnostics Inc.'s market cap moved from $245.43 Million to $ 96.86 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $96.86 Million | -60.53% |
| 2025 | $245.43 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Insight Molecular Diagnostics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $96.86 Million USD |
| MoneyControl | $96.86 Million USD |
| MarketWatch | $96.86 Million USD |
| marketcap.company | $96.86 Million USD |
| Reuters | $96.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expre… Read more